Amsterdam, 6 October 2021 – The World Health Organization published the latest edition of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children last week, which include new treatments for various cancers, insulin analogues and new oral medicines for diabetes, new medicines to assist people who want to stop smoking, and new antimicrobials to treat serious bacterial and fungal infections.

This is great news for global access to cancer medicines. When products are added to the WHO EML, they are often also added to national medicines lists in low- and middle-income countries (LMICs). IDA Foundation also recognises the importance of the EML and we use this list as a guideline for our own product portfolio, to make sure it is aligned with global demand.

Earlier this year we partnered with Pfizer to increase access to quality cancer treatment in LMICs. This partnership improves access to essential cancer medicines in 70 countries. Read more about this partnership in our recent blog post Partnership with Pfizer expands access to cancer treatments in 70 LMICs, and find more info in our Oncology portfolio.

Our annual Product Indicator provides customers with an overview of all IDA products available for order from IDA. This tool is aligned with the WHO EML, and highly appreciated by many of our customers to plan procurement of essential health goods for the coming months/years.

If you would like more information about our Oncology range, or ordering from IDA Foundation, get in touch with your IDA contact or register as a customer through our Customer Registration page.